source
- FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with NovoEli Lilly’s once-weekly basal insulin shot Onswik has been approved by the FDA for patients with type 2 diabetes. Lilly has touted Onswik as a longer-acting alternative to daily basal insulin injec…Endpoints · 1mo ago↗ source
- Roche and Ionis report positive Phase 3 interim results for IgA nephropathy drug sefaxersenRoche and Ionis announced that their experimental RNA therapy sefaxersen met its primary endpoint in an interim analysis of a Phase 3 trial for IgA nephropathy. The trial showed statistically sign…